| Serial Number | 88813300 |
| Word Mark | EBIOPARTICLE-POTENTIATED IMMUNOTHERAPY |
| Filing Date | Thursday, February 27, 2020 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, March 9, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | (Based on 44(d) Priority Application) (Based on Intent to Use) Protein arrays for medical diagnosis purposes; proteins arrays for therapeutic use for treating cancer, allergies, autoimmune disease, infection disease, and inflammatory disease; biopharmaceuticals for treatment of cancer, allergies, autoimmune disease, infection disease; pharmaceutical preparations for use in the treatment of allergy, cancer, infectious diseases and immune diseases; pharmacological preparations able to effect immunotherapy with specific attributes of potency and safety |
| Pseudo Mark | EBIOPARTICLE POTENTIATED IMMUNOTHERAPY |
| Goods and Services | (Based on 44(d) Priority Application) (Based on Intent to Use) Chemicals for use in the manufacture of pharmaceuticals; proteins for immunoassay for detection, for diagnostic purposes, for therapeutic purposes and for treatment of cancer, allergies, autoimmune disease, infection diseases; all of the foregoing expressly excluding biologically-derived particles that can be fluorescently-labeled for scientific research purposes |
| Goods and Services | (Based on 44(d) Priority Application) (Based on Intent to Use) Medical services, namely, vaccinal pharmacologic treatment of autoimmune diseases such as psoriasis, Crohn's disease, rheumatoid arthritis, cancer, infectious diseases and allergies; health care services, namely, desensitization treatments for allergy; medical services, namely, immunotherapy in the fields of cancer, autoimmune, infectious disease and orphan diseases conditions in humans and veterinary applications; medical treatment of allergies, cancer, and auto-immune diseases destined to generate, in response to its administration in patients, the production of the patient's own antibodies |
| Disclaimer with Predetermined Text | "IMMUNOTHERAPY" |
| Goods and Services | (Based on 44(d) Priority Application) (Based on Intent to Use) Development of pharmaceutical preparations and medicines; drug discovery services; software as a service (SAAS) services featuring artificial intelligence software for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining in the field of providing pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring artificial intelligence software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring computer software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical applications that is an immunomodulatory vector on which biologic targets determine the pertinence and use of these pharmacological agents |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 5, 2020 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 5, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 5, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 5, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Angany Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Quebec (Quebec) G1R1R2 CA |
| Event Date | Event Description |
| Thursday, March 9, 2023 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Thursday, March 9, 2023 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Thursday, March 9, 2023 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, January 17, 2023 | ASSIGNED TO EXAMINER |
| Thursday, August 25, 2022 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Thursday, August 25, 2022 | INQUIRY TO SUSPENSION E-MAILED |
| Thursday, August 25, 2022 | SUSPENSION INQUIRY WRITTEN |
| Thursday, August 25, 2022 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Thursday, February 24, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, February 24, 2022 | LETTER OF SUSPENSION E-MAILED |
| Thursday, February 24, 2022 | SUSPENSION LETTER WRITTEN |
| Thursday, February 3, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 3, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, January 26, 2022 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Wednesday, September 22, 2021 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Wednesday, September 22, 2021 | INQUIRY TO SUSPENSION E-MAILED |
| Wednesday, September 22, 2021 | SUSPENSION INQUIRY WRITTEN |
| Saturday, March 20, 2021 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Saturday, March 20, 2021 | LETTER OF SUSPENSION E-MAILED |
| Saturday, March 20, 2021 | SUSPENSION LETTER WRITTEN |
| Monday, February 22, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, February 22, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 22, 2021 | ASSIGNED TO LIE |
| Wednesday, November 18, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 18, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 18, 2020 | NON-FINAL ACTION E-MAILED |
| Monday, May 18, 2020 | NON-FINAL ACTION WRITTEN |
| Monday, May 18, 2020 | ASSIGNED TO EXAMINER |
| Thursday, March 5, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, March 5, 2020 | NEW APPLICATION ENTERED |